More importantly, when we compared transcriptomic profiles of multiple cancer types, we found that low RKIP expression usually correlated with high expression of prometastatic genes across different cancer types, suggesting that the RKIP-mimicking 4D-MAPKi treatment can be efficacious in a wide range of cancers. This evidence concerns the gene PEBP1 and cancer.